Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. CORT.NASDAQ

Corcept Therapeutics Incorporated (CORT NASDAQ) stock market data APIs

$35.39 -0.21(-0.6%) as of July 26, 2024
Price chart is built with Anychart

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Corcept Therapeutics Incorporated Financial Data Overview

35.6
35.39
-
35.95
34.9
20.84-35.95
3 630 M
33.2095
104 M
524 M
0.438
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'CORT',
Type: 'Common Stock',
Name: 'Corcept Therapeutics Incorporated',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000BKJG33',
ISIN: NULL,
CUSIP: NULL,
CIK: '1088856',
EmployerIdNumber: '77-0487658',
FiscalYearEnd: 'December',
IPODate: '2004-04-14',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Corcept Therapeutics Incorporated Fundamental Data is available in our Financial Data APIs

  • Net Revenue 524 M
  • EBITDA 123 M
  • Earnings Per Share 1.05
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Corcept Therapeutics Incorporated Earnings via APIs

  • Latest Release 2024-07-29
  • EPS/Forecast 0.23

Get Corcept Therapeutics Incorporated End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Corcept Therapeutics Incorporated latest news via APIs

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics Incorporated MENLO PARK, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial result...

Navigate Market Turbulence With These 4 Low-Beta Stocks

From late May through early July, economic activity in the United States experienced slight to modest growth, according to the Federal Reserve's Beige Book. However, businesses are expecting slower gr...
Do you have any questions?
support@eodhistoricaldata.com